EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)

Yutaka Ogata, Sotaro Sadahiro, Kazuhiro Sakamoto, Takashi Tsuchiya, Takao Takahashi, Hiroki Ohge, Toshihiko Sato, Ken Kondo, Hideo Baba, Michio Itabashi, Masataka Ikeda, Madoka Hamada und 8 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02565-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Yutaka Ogata und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan. yogata147@gmail.com. Hauptthemen laut MEDLINE: Tegafur, Uracil, Leucovorin, Propensity Score. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiho Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of adjuvant chemotherapy for high-risk stage II colon cancer (CC) has not been well established. Using propensity score matching, we previously reported that the 3-year disease-free survival (DFS) rate was significantly higher in patients treated with uracil and tegafur plus leucovorin (UFT/LV) against surgery alone. We report the final results, including updated 5-year overall survival (OS) rates and risk factor analysis outcomes.

Methods

In total, 1902 high-risk stage II CC patients with T4, perforation/penetration, poorly differentiated adenocarcinoma/mucinous carcinoma, and/or < 12 dissected lymph nodes were enrolled in this prospective, non-randomized controlled study based on their self-selected treatment. Oral UFT/LV therapy was administered for six months after surgery.

Results

Of the 1880 eligible patients, 402 in Group A (surgery alone) and 804 in Group B (UFT/LV) were propensity score-matched. The 5-year DFS rate was significantly higher in Group B than in Group A (P = 0.0008). The 5-year OS rates were not significantly different between groups. The inverse probability of treatment weighting revealed significantly higher 5-year DFS (P = 0.0006) and 5-year OS (P = 0.0122) rates in group B than in group A. Multivariate analyses revealed that male sex, age ≥ 70 years, T4, < 12 dissected lymph nodes, and no adjuvant chemotherapy were significant risk factors for DFS and/or OS.

Conclusion

The follow-up data from our prospective non-randomized controlled study revealed a considerable survival advantage in DFS offered by adjuvant chemotherapy with UFT/LV administered for six months over surgery alone in individuals with high-risk stage II CC.

Trial registration

Japan Registry of Clinical Trials: jRCTs031180155 (date of registration: 25/02/2019), UMIN Clinical Trials Registry: UMIN000007783 (date of registration: 18/04/2012).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TegafurUracilLeucovorinPropensity ScoreColonic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalNeoplasm StagingHumansMaleFemaleAgedMiddle AgedChemotherapy, AdjuvantProspective StudiesRisk FactorsAdultDisease-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

Adjuvant chemotherapyColon cancerHigh-risk stage IIInverse probability of treatment-weightingLeucovorinPropensity scoreRisk factorTegafurUracil

Substanzen

TegafurUracilLeucovorin

Autor:innen und Institutionen

  • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan. yogata147@gmail.com.
  • Department of Surgery, Tokai University, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
  • Department of Coloproctological Surgery, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan.
  • Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-Ku, Sendai, Miyagi, 983-0824, Japan.
  • Department of Digestive Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Department of Surgery, Seino Kosei Hospital, 293-1 Shimoiso Ono-Cho, Ibi-Gun, Gifu, 501-0532, Japan.

Förderung

  • Taiho Pharmaceutical

Zitieren

APA

Ogata, Y., Sadahiro, S., Sakamoto, K., Tsuchiya, T., Takahashi, T., Ohge, H., Sato, T., Kondo, K., Baba, H., Itabashi, M., Ikeda, M., Hamada, M., Maeda, K., Masuko, H., Takahashi, K., Kusano, M., Hyodo, I., Sakamoto, J., Taguri, M., & Morita, S. (2024). Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201). International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02565-5

Vancouver

Ogata Y, Sadahiro S, Sakamoto K, Tsuchiya T, Takahashi T, Ohge H, et al. Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201). International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02565-5

BibTeX
@article{Ogata2024,
  author = {Ogata, Yutaka and Sadahiro, Sotaro and Sakamoto, Kazuhiro and Tsuchiya, Takashi and Takahashi, Takao and Ohge, Hiroki and Sato, Toshihiko and Kondo, Ken and Baba, Hideo and Itabashi, Michio and Ikeda, Masataka and Hamada, Madoka and Maeda, Kiyoshi and Masuko, Hiroyuki and Takahashi, Keiichi and Kusano, Mitsuo and Hyodo, Ichinosuke and Sakamoto, Junichi and Taguri, Masataka and Morita, Satoshi},
  title = {Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02565-5}
}
Kostenlos starten →